Pembrolizumab and Lenvatinib for high-risk cervical cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests whether adding two drugs (pembrolizumab and lenvatinib) to standard chemoradiation and brachytherapy can improve outcomes for people with high-risk locally advanced cervical cancer. It is designed for patients who are fit enough to undergo intensive treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You are physically active enough to do light work (ECOG 0 or 1)
- You have a high-risk cervical cancer stage (e.g., stage III or certain stage IB to IIIC depending on cancer type)
- You are planning to receive chemoradiation and MR-guided brachytherapy within 50 days
- Your blood pressure is controlled (≤150/90 mmHg) with or without medication
- You have no major heart problems, active bleeding, or other cancers that need treatment
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
This trial tests if giving the immunotherapy drug pembrolizumab before and after standard chemoradiation works better than the standard approach for people with high-risk cervical cancer that has spread locally.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
This trial tests combining an immunotherapy drug (pembrolizumab) with a special type of radiation (carbon-ion radiotherapy) for a specific type of advanced cervical cancer called adenocarcinoma or adenosquamous carcinoma. It aims to see if this combination is safe and effective for patients who have not had prior radiation or chemotherapy for their cervical cancer.
This trial tests adding an immunotherapy drug (serplulimab) to standard chemoradiation after cervical cancer surgery. It is for patients with at least two high-risk features, like lymph node spread or deep invasion, to see if it helps prevent the cancer from coming back.
This trial tests a new combination of drugs for people with advanced cervical cancer that has come back or spread, and who have already tried standard treatments. It aims to see if adding these experimental drugs to lenvatinib is safe and effective.
Hear when a new Cervical Cancer by FIGO Stage 2018 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.